U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance
Aflibercept 2 mg was the most common drug used overall from 2017-2023. Faricimab had the highest absolute and relative increase in utilization from 2022-2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab.
Authors
- Sachi Patil
- Ravi Parikh (ORCID: https://orcid.org/0000-0003-3369-4224)
- Daniel Vail (ORCID: https://orcid.org/0000-0001-8769-2369)
- Kiran Preet Malhotra (ORCID: https://orcid.org/0000-0002-4400-9168)
- Joseph Colcombe
Institutions
- New York Eye and Ear Infirmary (US)
- NYU Langone Health (US)
- Vitreous Retina Macula Consultants of New York (US)
- New York University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1371/journal.pone.0335390
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 22.55